HomeGeneticsConditionPyruvate dehydrogenase deficiency
Back to Condition
Pyruvate dehydrogenase deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Pyruvate dehydrogenase deficiency

Pyruvate dehydrogenase deficiency is a rare condition characterized by the buildup of lactic acid in the body and a variety of neurological problems that typically appear shortly after birth.

Overview

Pyruvate dehydrogenase deficiency is a rare condition where the body cannot properly convert energy from food into a usable form for cells. This leads to a buildup of a chemical called lactic acid (lactic acidosis) and significant neurological impairment. Signs and symptoms vary widely but often include nausea, vomiting, breathing difficulties, and abnormal heartbeats. Because of the severity of these health effects, many individuals do not survive past childhood, though some may live into adolescence or adulthood.

Symptoms

Neurological and physical symptoms often manifest shortly after birth and may include:

  • Delayed development of mental abilities and motor skills (such as sitting and walking)
  • Intellectual disability
  • Seizures
  • Weak muscle tone (hypotonia)
  • Poor coordination and difficulty walking
  • Abnormal brain structures, such as underdevelopment of the corpus callosum, atrophy of the cerebral cortex, or lesions on the brain
  • Lactic acidosis, which can cause nausea, vomiting, severe breathing problems, and abnormal heartbeat

Causes

The condition is caused by mutations in genes that provide instructions for the pyruvate dehydrogenase complex. This complex is essential for converting pyruvate into acetyl-CoA, a critical step in cellular energy production. When this complex functions poorly, pyruvate builds up and is converted into lactic acid, while cellular energy production is diminished. The brain, which requires high amounts of energy, is particularly affected.

Associated Genes

  • DLAT
  • PDHA1
  • PDHB
  • PDHX
  • PDP1

Inheritance

Inheritance patterns depend on the specific gene involved:

  • X-linked inheritance: Mutations in the PDHA1 gene follow this pattern. In males, one mutated copy is sufficient to cause the condition. In females, the condition can be variable due to X-inactivation, where one X chromosome is turned off in each cell. Females with this condition often exhibit skewed X-inactivation, where the chromosome with the normal gene copy is inactivated in most cells.
  • Autosomal recessive inheritance: Mutations in other associated genes follow this pattern, meaning both copies of the gene in each cell must have mutations for the condition to occur. Parents of an affected individual typically do not show symptoms.

Frequently Asked Questions

Diagnosis usually begins with persistent lactic acidosis on blood gas and elevated lactate/pyruvate ratios. Confirmatory testing includes enzymatic activity measurement in cultured fibroblasts or muscle tissue, and targeted genetic sequencing of PDHA1, PDHB, DLAT, PDHX, and PDP1 genes.
Prognosis is highly variable. Severe X‑linked PDHA1 mutations often lead to early infant death from metabolic crises, while milder mutations or those affecting other subunits may allow survival into adolescence or adulthood with significant neurodevelopmental impairment. Early diagnosis, aggressive metabolic management, and multidisciplinary support improve quality of life and can extend survival.
Seizure control follows standard antiepileptic drug protocols, but clinicians prefer agents with minimal mitochondrial toxicity (e.g., levetiracetam, valproate with caution). Regular EEG monitoring is recommended. In addition, optimizing metabolic control (thiamine, ketogenic diet) can reduce seizure frequency. Ongoing neuro‑rehabilitation and early educational interventions are crucial for maximizing functional abilities.
First‑line therapy often includes high‑dose thiamine (vitamin B1) because the PDH complex requires thiamine as a cofactor. A ketogenic (high‑fat, low‑carbohydrate) diet can bypass the block by providing ketone bodies as an alternative fuel for the brain. In some centers, dichloroacetate (DCA) is trialed to stimulate PDH activity, but its long‑term safety is still under study. Supportive care such as physical, occupational, and speech therapy is essential for developmental progress.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA